Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Oncological Medicine
Volume 2016, Article ID 6980198, 4 pages
http://dx.doi.org/10.1155/2016/6980198
Case Report

A Novel Case of Penile Gangrene in a Patient Treated with Ibrutinib for Chronic Lymphocytic Leukemia

1Department of Internal Medicine, University of Florida, Gainesville, FL, USA
2Department of Internal Medicine, University of Central Florida, Orlando, FL, USA
3Cancer Specialists of North Florida, Saint Augustine, FL, USA
4Division of Hematology and Oncology, Department of Internal Medicine, University of Florida, Gainesville, FL, USA

Received 24 July 2016; Accepted 6 November 2016

Academic Editor: Raffaele Palmirotta

Copyright © 2016 William Paul Skelton IV et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. N. Chiorazzi, K. R. Rai, and M. Ferrarini, “Chronic lymphocytic leukemia,” The New England Journal of Medicine, vol. 352, no. 8, pp. 804–850, 2005. View at Publisher · View at Google Scholar · View at Scopus
  2. G. Gaidano, R. Foà, and R. Dalla-Favera, “Molecular pathogenesis of chronic lymphocytic leukemia,” Journal of Clinical Investigation, vol. 122, no. 10, pp. 3432–3438, 2012. View at Publisher · View at Google Scholar · View at Scopus
  3. Y. Kikushige, F. Ishikawa, T. Miyamoto et al., “Self-renewing hematopoietic stem cell is the primary target in pathogenesis of human chronic lymphocytic leukemia,” Cancer Cell, vol. 20, no. 2, pp. 246–259, 2011. View at Publisher · View at Google Scholar · View at Scopus
  4. G. A. Calin, C. D. Dumitru, M. Shimizu et al., “Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia,” Proceedings of the National Academy of Sciences of the United States of America, vol. 99, no. 24, pp. 15524–15529, 2002. View at Publisher · View at Google Scholar · View at Scopus
  5. M. Hallek, “Chronic lymphocytic leukemia: 2015 update on diagnosis, risk stratification, and treatment,” American Journal of Hematology, vol. 90, no. 5, pp. 446–460, 2015. View at Publisher · View at Google Scholar · View at Scopus
  6. G. Dighiero, K. Maloum, B. Desablens et al., “Chlorambucil in indolent chronic lymphocytic leukemia,” The New England Journal of Medicine, vol. 338, no. 21, pp. 1506–1514, 1998. View at Publisher · View at Google Scholar · View at Scopus
  7. Group CLLTC, “Chemotherapeutic options in chronic lymphocytic leukemia: a meta-analysis of the randomized trials,” Journal of the National Cancer Institute, vol. 91, no. 10, pp. 861–868, 1999. View at Publisher · View at Google Scholar
  8. M. Hallek, K. Fischer, G. Fingerle-Rowson et al., “Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial,” The Lancet, vol. 376, no. 9747, pp. 1164–1174, 2010. View at Publisher · View at Google Scholar · View at Scopus
  9. L. Smolej and M. Šimkovič, “Practical approach to management of chronic lymphocytic leukemia,” Archives of Medical Sciences, vol. 12, no. 2, pp. 448–456, 2016. View at Google Scholar
  10. S. E. M. Herman, A. L. Gordon, E. Hertlein et al., “Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765,” Blood, vol. 117, no. 23, pp. 6287–6296, 2011. View at Publisher · View at Google Scholar · View at Scopus
  11. J. A. Burger, A. Tedeschi, P. M. Barr et al., “Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia,” The New England Journal of Medicine, vol. 373, no. 25, pp. 2425–2437, 2015. View at Publisher · View at Google Scholar · View at Scopus
  12. J. C. Byrd, R. R. Furman, S. E. Coutre et al., “Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia,” The New England Journal of Medicine, vol. 369, no. 1, pp. 32–42, 2013. View at Publisher · View at Google Scholar · View at Scopus
  13. G. K. Dy and A. A. Adjei, “Understanding, recognizing, and managing toxicities of targeted anticancer therapies,” CA: a Cancer Journal for Clinicians, vol. 63, no. 4, pp. 249–279, 2013. View at Publisher · View at Google Scholar · View at Scopus
  14. V. Singh, R. J. Sinha, and S. N. Sankhwar, “Penile gangrene: a devastating and lethal entity,” Saudi Journal of Kidney Diseases and Transplantation, vol. 22, no. 2, pp. 359–361, 2011. View at Google Scholar · View at Scopus